<DOC>
	<DOCNO>NCT01757860</DOCNO>
	<brief_summary>Study Phase : Phase 1 Primary Objective : • To evaluate safety tolerability single ascend oral dos CARD-024 healthy subject Secondary Objectives : - To evaluate pharmacokinetic ( PK ) profile CARD-024 follow ascend single oral dos CARD-024 - To evaluate effect CARD-024 cardiovascular index include plasma renin activity ( PRA ) blood pressure ( BP ) , biological marker activity , follow ascend single oral dos CARD-024</brief_summary>
	<brief_title>Safety Pharmacokinetics Study CARD-024 Healthy Subjects</brief_title>
	<detailed_description>Study Design : This single-center , double-blind , randomize , placebo-controlled study single oral dos CARD-024 . Four plan cohort 8 subject dose sequentially randomize receive single dose active drug ( 6 subject ) placebo ( 2 subject ) . Cohort 4 10 subject randomize receive active drug ( 7 subject ) placebo ( 3 subject ) . Each cohort divide least 2 group ; first group 2 subject , 1 receive active drug 1 receiving placebo . Dosing remain 6 subject cohort complete manner agree upon Sponsor Principal Investigator keep randomization schedule blind condition . The planned cohort : Cohort CARD-024 Dose* 1 . 3 μg 2 . 9 μg 3 . 27 μg 4 . 81 μg</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<criteria>1 . Healthy male female age 18 55 , inclusive , body mass index ( BMI ) 1832 kg/m2 . 2 . Females must surgically sterile least 2 year postmenopausal . Menopausal status verify follicular stimulate hormone ( FSH ) test . Those bilateral tubal ligation must also use barrier method birth control . In addition , female must negative pregnancy test Screening . 3 . No clinically significant finding physical examination , include BP , pulse rate 12lead ECG . No clinically significant medical history . 4 . No clinically significant safety laboratory result Screening . Cardiavent , Inc . CONFIDENTIAL 5 . Nonsmoker light smoker ( ≤5 cigarette per day similar use tobacco product ) willing refrain smoking clinic . 6 . Willing able sign inform consent document indicate understand purpose procedure require study willingness participate study . 7 . Willing able stay clinic inpatient activity require protocol visit . 1 . Evidence clinically relevant pathology could interfere study result put subject 's safety risk . 2 . Current recurrent disease may affect action , absorption , disposition study treatment , clinical laboratory assessment . 3 . Current relevant previous history serious , severe , unstable ( acute progressive ) physical psychiatric illness , medical disorder require treatment may make subject unlikely fully complete study , condition present undue risk study treatment procedure . 4 . History febrile illness within 5 day prior first dose . 5 . Positive Hepatitis B surface antigen ( HbsAg ) , Hepatitis C antibody Human Immunodeficiency Virus ( HIV ) test result Screening visit . 6 . Use prescription medication overthecounter ( OTC ) medication within 7 day 5 halflives ( whichever longer ) prior first dose trial medication study . As exception , acetaminophen may use dos 1 g/day . 7 . Use herbal supplement ( include herbal weightloss `` metabolism booster '' therapy ) within 30 day prior first dose trial medication . 8 . Known suspected intolerance hypersensitivity similar study drug excipients , closely related compound state ingredient . 9 . Positive screen alcohol drug abuse Screening visit study checkin Day 1 dosing . 10 . Participated clinical study involve investigational drug within 30 day 5 halflives ( whichever longer ) prior study drug administration . 11 . Blood donation 1 pint within 56 day start study . 12 . Plasmapheresis plasma donation within 30 day start study . 13 . Single 12lead ECG demonstrate QTc &gt; 450 msec Screening , history evidence long QT syndrome . A single repeat ECG may do Principal Investigator 's discretion . 14 . Any condition opinion Principal Investigator would complicate compromise study wellbeing subject . 15 . Unwilling unable comply clinic house rule .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>